Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.

ABSTRACT:

Introduction

Over the past few years, trials evaluating immunotherapies, particularly immune checkpoint inhibitors, have revolutionized the standard model of cancer treatment, demonstrating significant antitumor responses and improved clinical outcomes across a wide array of tumors types. Yet, despite these compelling data, a major limitation has been that only a fraction of patients mount a response to single-agent immune checkpoint inhibition. However, a growing amount of preclinical and clinical data suggests that combining immune checkpoint inhibition, either with other immune checkpoint inhibitors or with therapeutic cancer vaccines, has the potential to improve the proportion of patients seeing long-term durable responses with these therapies.

Areas covered

We have rev

SUBMITTER: Strauss J 

PROVIDER: S-EPMC6599515 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature